EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association of germline BRCA and homologous recombination deficiency with hematologic toxicity during platinum–taxane chemotherapy in ovarian cancer

Kosuke Yoshida, Hajime Araki, Yurika Yamada, Yoshiki Masahashi, Emiri Miyamoto, Komei Katayama, Mei Kubokawa, Kazumasa Mogi, Masato Yoshihara, Yukari Nagao, Satoshi Tamauchi, Akira Yokoi und 3 weitere

International Journal of Clinical Oncology · 2026-08 · 31 (8) · 1576-1586

DOI: 10.1007/s10147-026-03065-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 27.05.2026. Verfasst von Kosuke Yoshida und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsuruma-cho 65, Showa-ku, Nagoya, 466-8550, Japan. yoshida.ko…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, BRCA2 Protein, BRCA1 Protein, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nagoya University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Germline BRCA (gBRCA) mutations and homologous recombination deficiency (HRD) are critical factors affecting treatment response; however, their association with hematologic toxicity remains controversial. This study assessed the interplay between these molecular features and hematologic adverse events during platinum–taxane chemotherapy.

Methods

We retrospectively reviewed 62 patients with stage III–IV ovarian cancer between 2022 and 2024. After excluding 8 patients, 54 patients were stratified according to gBRCA and HRD status, and hematologic adverse events were evaluated for up to six treatment cycles. Moreover, meta-analysis was performed to integrate previously published data.

Results

First, after excluding patients with uncertain gBRCA status, eight gBRCA mutation carriers were compared with 33 confirmed non-carriers. gBRCA mutation carriers tended to exhibit lower neutrophil counts during treatment; however, no statistically significant differences in hematologic toxicities were observed across treatment cycles. In the pooled meta-analysis, gBRCA mutation carriers demonstrated significantly increased odds of neutropenia (odds ratio [OR] 1.68, 95% confidence interval [CI] 1.16–2.44) and G-CSF use (OR 3.09, 95% CI 1.19–8.03), whereas no significant associations were observed for anemia, thrombocytopenia, dose delay, or dose reduction. Second, 23 HRD-positive patients and 15 HRD-negative patients were analyzed. HRD-positive patients did not demonstrate increased hematologic toxicity compared with HRD-negative patients. Although baseline hemoglobin levels were lower in HRD-positive patients, these differences preceded chemotherapy initiation.

Conclusion

This study provides real-world evidence of a modestly increased risk of neutropenia and G-CSF use in gBRCA carriers during platinum–taxane chemotherapy; however, these differences did not appear to compromise treatment delivery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsBRCA2 ProteinBRCA1 ProteinAntineoplastic Combined Chemotherapy ProtocolsTaxoidsHumansFemaleGerm-Line MutationMiddle AgedAgedRetrospective StudiesHomologous RecombinationAdultNeutropeniaBridged-Ring Compounds

Stichwörter der Autor:innen

Germline BRCAHematologic toxicityHomologous recombination deficiencyOvarian cancerPlatinum–taxane chemotherapy

Substanzen

BRCA2 ProteinBRCA1 ProteinBRCA2 protein, humanBRCA1 protein, humanTaxoidsBridged-Ring Compoundstaxane

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsuruma-cho 65, Showa-ku, Nagoya, 466-8550, Japan. yoshida.kousuke@med.nagoya-u.ac.jp.
  • Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsuruma-cho 65, Showa-ku, Nagoya, 466-8550, Japan.
  • Department of Medical Genomics Center, Nagoya University Hospital, Nagoya, Japan.

Förderung

  • Nagoya University

Zitieren

APA

Yoshida, K., Araki, H., Yamada, Y., Masahashi, Y., Miyamoto, E., Katayama, K., Kubokawa, M., Mogi, K., Yoshihara, M., Nagao, Y., Tamauchi, S., Yokoi, A., Yoshikawa, N., Niimi, K., & Kajiyama, H. (2026). Association of germline BRCA and homologous recombination deficiency with hematologic toxicity during platinum–taxane chemotherapy in ovarian cancer. International Journal of Clinical Oncology, 31(8), 1576-1586. https://doi.org/10.1007/s10147-026-03065-4

Vancouver

Yoshida K, Araki H, Yamada Y, Masahashi Y, Miyamoto E, Katayama K, et al. Association of germline BRCA and homologous recombination deficiency with hematologic toxicity during platinum–taxane chemotherapy in ovarian cancer. International Journal of Clinical Oncology. 2026;31(8):1576-1586. doi:10.1007/s10147-026-03065-4

BibTeX
@article{Yoshida2026,
  author = {Yoshida, Kosuke and Araki, Hajime and Yamada, Yurika and Masahashi, Yoshiki and Miyamoto, Emiri and Katayama, Komei and Kubokawa, Mei and Mogi, Kazumasa and Yoshihara, Masato and Nagao, Yukari and Tamauchi, Satoshi and Yokoi, Akira and Yoshikawa, Nobuhisa and Niimi, Kaoru and Kajiyama, Hiroaki},
  title = {Association of germline BRCA and homologous recombination deficiency with hematologic toxicity during platinum–taxane chemotherapy in ovarian cancer},
  journal = {International Journal of Clinical Oncology},
  year = {2026},
  volume = {31},
  number = {8},
  pages = {1576--1586},
  doi = {10.1007/s10147-026-03065-4}
}
Kostenlos starten →